[PharmaEssentia] Announcement of significant resolutions from the 2026 annual general meeting (acting by the Board) of major subsidiary FanTai Medical Products Co., Ltd.
PharmaEssentia's major subsidiary, FanTai Medical Products Co., Ltd., held its 2026 annual general meeting, approving the 2025 financial report and the loss recovery plan.
📋 Article Processing Timeline
- 📰 Published: May 15, 2026 at 09:00
- 🔍 Collected: May 16, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 16, 2026 at 11:50 (3h 50m after Collected)
1. Date of annual general meeting: 2026/05/15
2. Important resolution I, distribution of surplus or compensation for losses: Approved the loss recovery plan for 2025.
3. Important resolution II, revision of articles of incorporation: None.
4. Important resolution III, business report and financial statements: Approved the 2025 financial report and business report.
5. Important resolution IV, election of directors and supervisors: None.
6. Important resolution V, other matters: None.
7. Other matters to be stated: None.
2. Important resolution I, distribution of surplus or compensation for losses: Approved the loss recovery plan for 2025.
3. Important resolution II, revision of articles of incorporation: None.
4. Important resolution III, business report and financial statements: Approved the 2025 financial report and business report.
5. Important resolution IV, election of directors and supervisors: None.
6. Important resolution V, other matters: None.
7. Other matters to be stated: None.